Ono Pharmaceutical (OPHLF) Projected to Announce Earnings on Wednesday

Ono Pharmaceutical (OTCMKTS:OPHLF) is expected to be issuing its results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $0.26 per share and revenue of $728.39 million for the quarter.

Ono Pharmaceutical Price Performance

OPHLF stock opened at $15.16 on Wednesday. The firm has a market cap of $7.12 billion, a P/E ratio of 13.42 and a beta of 0.38. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.86 and a current ratio of 3.28. Ono Pharmaceutical has a 1 year low of $11.08 and a 1 year high of $18.67. The stock has a 50-day simple moving average of $15.11 and a 200-day simple moving average of $14.68.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One analyst has rated the stock with a Hold rating. According to MarketBeat.com, Ono Pharmaceutical presently has an average rating of “Hold”.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.